CRVS · Corvus Pharmaceuticals, Inc.
$13.04
-0.27 (-2.03%)
At close · Jul 29
Market Cap
$1.12B
Shares
84.09M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Ian T. Clark | board of directors | Resigned | 2026-07-22 |
| Scott Morrison | Board | Resigned | 2026-04-23 |
| Andrew C. Chan, M.D., Ph.D. | Class II director | Appointed | 2026-04-23 |
Key facts
CIK
1626971
CUSIP
221015100
13F (30d)
23 filings
23 filers
Visit website
Investor relations